#1 Clinical Trials Search in Europe

Brivaracetam

Brivaracetam, also known by its brand name Briviact, is an antiepileptic drug that has been the subject of numerous clinical trials. These studies aim to evaluate its efficacy, safety, and pharmacokinetics in treating various forms of epilepsy, particularly partial-onset seizures. The trials involve diverse patient populations, including adults, adolescents, and children, and explore different administration methods such as oral tablets, oral solutions, and intravenous injections.

Table of Contents

What is Brivaracetam?

Brivaracetam is an antiepileptic drug (AED) used to treat epilepsy. It is also known by its brand name Briviact[1][2]. Brivaracetam belongs to a class of medications called anticonvulsants, which are drugs designed to prevent or reduce the frequency of seizures in people with epilepsy.

Uses of Brivaracetam

Brivaracetam is primarily used to treat partial-onset seizures in patients with epilepsy. Partial-onset seizures, also known as focal seizures, are a type of epileptic seizure that starts in one area of the brain. These seizures can occur with or without secondary generalization, which means they may spread to involve both sides of the brain[3][4].

There are three main types of partial seizures that Brivaracetam can help with:

  • Simple Partial Seizures: The person remains conscious but may experience unusual sensations or movements.
  • Complex Partial Seizures: The person’s consciousness is altered, and they may appear confused or perform repetitive movements.
  • Partial Seizures evolving to Secondarily Generalized Seizures: The seizure starts in one area of the brain but then spreads to both sides, potentially causing a convulsion[3].

How Brivaracetam Works

While the exact mechanism of action is not fully understood, Brivaracetam is believed to work by binding to a protein in the brain called synaptic vesicle protein 2A (SV2A). This interaction is thought to help regulate the release of neurotransmitters (chemical messengers) in the brain, which may help to reduce abnormal electrical activity that causes seizures[3].

Forms and Administration

Brivaracetam is available in several forms to suit different patient needs:

  • Oral tablets: Film-coated tablets in strengths of 10 mg, 25 mg, 50 mg, and 100 mg[2].
  • Oral solution: A liquid form with a concentration of 10 mg/mL, which may be easier for some patients to swallow[5].
  • Intravenous (IV) injection: A solution for injection with a concentration of 10 mg/mL, which can be used when oral administration is temporarily not feasible[6].

Brivaracetam is typically taken twice daily, in the morning and evening, with or without food. The dosage is usually adjusted based on the patient’s age, weight, and response to treatment[5].

Efficacy and Safety

Clinical trials have shown that Brivaracetam is effective in reducing the frequency of partial-onset seizures in patients with epilepsy. In one study, patients taking Brivaracetam experienced a significant reduction in seizure frequency compared to those taking a placebo[3].

The safety profile of Brivaracetam has been evaluated in both short-term and long-term studies. These studies have shown that Brivaracetam is generally well-tolerated, with most side effects being mild to moderate in severity[4].

Side Effects

Like all medications, Brivaracetam can cause side effects. The most common side effects reported in clinical trials include:

  • Drowsiness or sleepiness: This can affect your ability to drive or operate machinery.
  • Dizziness: This may increase the risk of falls, especially in older adults.
  • Nausea: Taking the medication with food may help reduce this side effect.
  • Fatigue: You may feel more tired than usual.
  • Headache: This is usually mild and may improve over time.

It’s important to note that not everyone experiences these side effects, and they often improve as your body adjusts to the medication. Always report any persistent or severe side effects to your healthcare provider[3].

Special Populations

Brivaracetam has been studied in various age groups:

  • Adults: Most studies have focused on adults aged 16 to 80 years old[3].
  • Children and adolescents: Ongoing research is evaluating the safety and efficacy of Brivaracetam in patients from 1 month to 16 years of age[6].
  • Elderly: Studies have included patients up to 80 years old, but caution is advised as older adults may be more sensitive to side effects[3].

The use of Brivaracetam during pregnancy and breastfeeding should be discussed with a healthcare provider, as the potential risks and benefits need to be carefully considered.

Ongoing Research

Several clinical trials are currently underway to further investigate the use of Brivaracetam:

  • Long-term safety and efficacy studies in adults and children[5].
  • Studies evaluating the use of Brivaracetam as monotherapy (used alone) for epilepsy[7].
  • Research on the pharmacokinetics (how the body processes the drug) in different populations, including Chinese patients[2].
  • Investigations into the use of intravenous Brivaracetam in situations where oral administration is not possible[1].

These ongoing studies aim to provide more information about the long-term use of Brivaracetam and its potential benefits in different patient groups.

Aspect Details
Drug Name Brivaracetam (Briviact)
Primary Use Treatment of partial-onset seizures in epilepsy
Age Groups Studied 1 month to 75 years old
Administration Methods Oral tablets, oral solutions, intravenous injections
Key Outcome Measures Seizure frequency reduction, responder rates, safety/tolerability, pharmacokinetics
Study Types Bioequivalence, long-term safety, efficacy, pharmacokinetics
Special Populations Pediatric patients, Japanese subjects
Treatment Approaches Adjunctive therapy, conversion to monotherapy
Safety Assessments Adverse events, serious adverse events, tolerability
Quality of Life Measures QOLIE-31-P, Hospital Anxiety and Depression Scale

FAQ

  • What is Brivaracetam? Brivaracetam is an antiepileptic drug used to treat partial-onset seizures in patients with epilepsy. It's also known by its brand name Briviact and is being studied for its efficacy and safety in various patient populations.
  • What types of seizures is Brivaracetam being studied for? Brivaracetam is primarily being studied for partial-onset seizures, which can be simple partial seizures, complex partial seizures, or partial seizures evolving to secondarily generalized seizures. Some trials also evaluate its effect on other types of seizures.
  • What age groups are included in Brivaracetam clinical trials? Clinical trials for Brivaracetam include a wide range of age groups, from infants as young as 1 month old to adults up to 75 years of age. Different studies focus on specific age ranges, such as 16 to 70 years, or pediatric populations from 1 month to under 16 years.
  • How is Brivaracetam administered in these trials? Brivaracetam is administered in various forms depending on the trial. These include oral tablets, oral solutions, and intravenous (IV) injections. Some studies compare different administration methods, such as transitioning from oral to IV administration.
  • What are the main outcomes measured in Brivaracetam trials? The main outcomes measured in Brivaracetam trials include reduction in seizure frequency, responder rates (percentage of patients with 50% or greater reduction in seizures), safety and tolerability (adverse events), pharmacokinetics (drug concentration in plasma), and quality of life measures for patients with epilepsy.

Ongoing Clinical Trials on Brivaracetam

  • Study on Fast Sedation with Propofol and Midazolam vs. Anti-Seizure Drug Combination for Treating Refractory Status Epilepticus in Intensive Care Patients

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study on the Long-Term Safety of Brivaracetam for Children and Young Adults with Childhood or Juvenile Absence Epilepsy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Romania Slovakia Spain

  • Study of brivaracetam as a treatment for childhood and juvenile absence epilepsy in patients aged 2-25 years

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Romania Slovakia Spain

Glossary

  • Brivaracetam: An antiepileptic drug used to treat partial-onset seizures, also known by its brand name Briviact.
  • Partial-onset seizures: Seizures that start in a specific area of the brain, which can be simple partial, complex partial, or evolve to secondarily generalized seizures.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Bioequivalence: The property of two drug products having the same biological effect and availability in the body.
  • Adjunctive treatment: A therapy used in addition to the primary or initial treatment to maximize its effectiveness.
  • Monotherapy: The use of a single drug to treat a particular disorder or disease.
  • Responder rate: The percentage of patients who have a 50% or greater reduction in seizure frequency compared to baseline.
  • Adverse event (AE): Any undesirable experience associated with the use of a medical product in a patient.
  • Serious adverse event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.
  • Quality of Life in Epilepsy Inventory (QOLIE): A standardized questionnaire used to assess the quality of life in patients with epilepsy.
  • Intravenous (IV) administration: The delivery of a medication directly into a vein using a needle or tube.
  • Plasma concentration: The amount of a drug present in the blood plasma at a given time.
  • Half-life: The time it takes for the concentration of a drug in the body to be reduced by half.
  • Area Under the Curve (AUC): A measure of the body's exposure to a drug over time, used in pharmacokinetic studies.

References

  1. https://clinicaltrials.gov/study/NCT03685630
  2. https://clinicaltrials.gov/study/NCT04882540
  3. https://clinicaltrials.gov/study/NCT00490035
  4. https://clinicaltrials.gov/study/NCT03250377
  5. https://clinicaltrials.gov/study/NCT04715646
  6. https://clinicaltrials.gov/study/NCT03405714
  7. https://clinicaltrials.gov/study/NCT00699283